Andrew Mackie, chief business officer of Ergomed Plc (LON: ERGO), says the company is looking for more opportunities to expand via acquisition principally specialist service companies operating in the post-marketing arena.
The pharma services specialist has just bought Haemostatix and its pipeline of topical products to treat surgical bleeding. Mackie is confident the products could get to market quickly and economically, but tells investors there are earlier monetisation moments in terms of deals with licencing partners.
Concurrent with this week’s acquisition, Ergomed raised £9 million to assist the development of Haemostatix products and fund bolt on acquisitions to cover geographical holes globally and enhance service delivery.
